Ovarian and Prostate Cancer (PARPi) [Tissue, Somatic]
BRCA1, BRCA2 and HRR testing for Ovarian and Prostate cancer in the context of PARP inhibitor prescription (FFPE). This EQA is sponsored.
Sponsored by
, 
Overview
The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.
At a glance
Product Code:
02-PARPIS-27
Target/Genes:
The scope of this EQA involves, testing for variants in the BRCA1, BRCA2 and other HRR genes in ovarian and prostate cancers in the context of PARP inhibitors therapy.
NOT suitable for labs testing for recurrent variants only.
Technology:
CNV, NGS, Panel testing
Sample Type:
FFPE
Submit Results In:
English, French, German, Italian, Spanish
Accredited:
Yes
Key Dates
28/02/2027
Sep-27
September - November 2027
May - June 2028
Sample Details
Three mock clinical cases with matching samples. Samples provided are real human tumour tissue paraffin embedded (FFPE) and/or artificial FFPE (designed to simulate real patient samples). One 10um FFPE section per case is provided.
Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
EQA Results
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participation Information
Participants are expected to test samples according to their routine strategy, to return a clinical report with interpretation in the context of targeted PARP inhibitor treatment for the tumour type, and to complete the data collection form.
This EQA is supported by an educational grant from AstraZeneca and MSD, fees are subsidised so there is a reduced cost for participants. The EQA providers acknowledge and thank AstraZeneca and MSD for this support.
The number of participants is limited, please register early to make sure you don’t miss out.
Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
This EQA is provided in collaboration with GenQA.
Send your enquiry by submitting the form
Closes in 111 days
From £465.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
- ISO 17043 accredited scheme
- Submit results in 5 languages
Questions about this scheme?
Contact our team
Register Interest
Express your interest in ''.